



## Continuing Education Credit Information

### Cutting Edge of Transplantation Transplant Summit 2026 The Power of Innovation: Turning Challenges into Opportunities

February 26<sup>th</sup> – February 28<sup>th</sup>, 2026  
Westin Kierland Hotel  
Scottsdale, AZ

This activity is jointly provided by Global Education Group (Global) and American Society of Transplantation.



This activity is supported by educational grants from Takeda Pharmaceuticals U.S.A, Inc., United Therapeutics Corporation and Veloxis Pharmaceuticals, Inc. and in part by educational grants from Apellis Pharmaceuticals, Inc. and Bristol Myers Squibb.

## Program Description and Learning Objectives

### **Target Audience**

The target audience for Cutting Edge of Transplantation (CEoT) 2026 includes clinicians such as physicians, nurses, nurse practitioners, physician associates, and allied healthcare practitioners. The target audience also includes scientists, trainees, organ donation professionals, and patients in the field of solid organ transplantation and donation interested in the pragmatic and practical aspects of transplantation.

### **Statement of Need/Program Overview**

The CEoT meeting brings together clinical and translational experts from the fields of chronic disease, end-stage organ disease, and solid organ transplantation. This interactive forum is designed to deepen understanding of advances in clinical transplantation and regulatory policies that impact transplantation, while also providing solutions and tools to integrate these advances into clinical practice.

Recent policy changes have significantly impacted the organ transplant and donation ecosystem, including the HRSA OPTN Modernization Initiative, cuts in research funding for transplantation science, and disruption of the integrated networks that support transplantation, such as downsizing at the Centers for Disease Control and HRSA. The overarching goal of CEoT 2026 is to address these challenges and to explore opportunities to continue improving patient care and expanding clinical and research impact.



### **Conference Learning Objectives:**

Following this activity, attendees should be able to:

1. Discuss how relevant policy and funding issues in transplant affect innovation.
2. Review innovative opportunities for funding and research that are both pragmatic and impactful.
3. Identify cutting-edge innovations in the transplant system to enhance the efficiency and effectiveness of organ donation and transplantation.
4. Describe the future of a modern transplant system including how healthcare delivery can be best coordinated, integrated, and supported across the entire system.

### **CME-Accredited Session Learning Objectives:**

#### **Session 2 Learning Objectives:**

Following this session, attendees should be able to:

1. Describe what a surrogate endpoint in a clinical trial is and how it can be used to spur innovation in transplant.
2. List examples of how real-world evidence has been used to obtain FDA approved indication in transplantation and beyond.
3. Discuss how biomarkers can be used to accelerate clinical research by improving the efficiency of trial conduct.

#### **Session 3 Learning Objectives:**

Following this session, attendees should be able to:

1. Describe the spectrum of current deceased donor research focused on improving organ recovery and patient outcomes.
2. Review the core regulatory challenges associated with designing clinical trials involving deceased organ donors with a focus on lung donation and transplantation.
3. Describe current innovations in genomics and donor research from perspectives of donor next of kin, clinicians and researchers to advance medicine.

#### **Keynote Address Learning Objectives:**

Following this session, attendees should be able to:

1. Define health disparities based on demographic and social constructs within the contemporary U.S. healthcare context based on scientific evidence and population-level data.
2. Evaluate potential evidence-based strategies, including their application, to reduce healthcare disparities with the goal of improving health outcomes across patient populations.
3. Identify how health policies developed and implemented at local, state, and national levels, impact healthcare, patients and communities.



### **Session 5 Kidney Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Identify challenges and opportunities in sustaining successful transplant centers.
2. Discuss strategies to address workforce shortages in transplantation.
3. List novel approaches to organizing transplant care.

### **Session 5 Heart Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Describe issues with the current allocation scheme, and how Continuous Distribution may help
2. Identify unforeseen consequences potentially affecting pediatric candidates from changes in pediatric heart or even adult heart or multi-organ allocation
3. Review implications, outcomes, quality, finances – of current and future transport and preservation technology

### **Session 5 Liver Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Describe recent advances in national liver allocation and how continuous distribution can contribute equitable access to liver transplant care.
2. Identify cost-effective and value-driven center-level considerations related to liver perfusion logistics
3. Discuss clinical implications of on-site vs back to base perfusion initiation protocols

### **Session 5 Lung Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Describe allocation challenges across the lung transplant system including the perspective from the OPO, transplant centers, and system leaders.
2. Review the impact of the recent allocation change and visualize elements of the next allocation through the lens of continuing to improve equity.
3. Define opportunities for future optimization of allocation challenges.

### **Session 6 Kidney Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Review the current islet replacement strategies in the management of type 1 DM.
2. Discuss how newer therapies may allow patients with some cancers safer for transplant.
3. Describe the new modalities of desensitization for allowing transplant in highly sensitized kidney transplant candidates.



### **Session 6 Heart Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Identify gaps in device development pipeline.
2. Describe barriers to candidacy and access.
3. Discuss whether devices can become the destination therapy. If not, how can they buffer demand?

### **Session 6 Lung Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Examine new therapeutics in advanced lung disease and describe the potential of these therapies to delay or avoid lung transplant in the future.
2. Describe opportunities for expansion of recipient access to transplant by challenging accepted recipient selection practices specifically regarding advanced age, high comorbidity burden, oncologic survivors and frailty.
3. Identify disparities in the referral to transplant process and develop implementable solutions to decrease transplant disparities by 2035.

### **Session 6 Liver Breakout Learning Objectives:**

Following this session, attendees should be able to:

1. Describe how evolving concepts of abundance in organ availability may alter adult liver transplant candidate selection and listing practices.
2. Assess the impact of genomic medicine and changing pediatric liver disease epidemiology on future pediatric transplant candidacy.
3. Evaluate surgical and programmatic considerations that will shape the design of liver transplant waitlists by 2035, including equity, allocation, and institutional capacity.

### **CME Lunch Symposium #1 - A New Frontier for Co-stimulatory Blockade:**

1. Describe the immune mechanism of co-stimulation
2. Review the uses benefits and risks of co-stimulatory blockage after transplantation: potential for new patient populations
3. Describe how co-stimulatory blockade could be utilized in desensitization of patients with high level anti-HLA antibodies

### **CME Lunch Symposium #2 - Mechanisms and Treatment of Immune Complex GN and C3 GN**

1. Describe the mechanistic drivers behind IC GN and C3 GN
2. Discuss the factors predicting outcomes of ICGN and C3GN after transplantation
3. Discuss treatment options for ICGN and C3 GN

### **Faculty**

Please view the faculty within the program agenda at the link [here](#).



### **Program Agenda**

Please view the entire program at the link [here](#).

### **Physician Accreditation Statement**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and American Society of Transplantation. Global is accredited by the ACCME to provide continuing medical education for physicians.

### **Physician Credit Designation**

Global Education Group designates this live activity for a maximum of 8.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **ABIM MOC Recognition Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### **Nursing Continuing Education**

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 8.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

### **Pharmacist Accreditation Statement**



Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

### **Credit Designation**

Global Education Group designates this continuing education activity for 8.5 contact hour(s) (.85 CEUs) of the Accreditation Council for Pharmacy Education.

*This is a knowledge-based activity.*



Please see [CEoT Meeting Accreditation](#) and click on the CME Packet for full ACPE information and UAN numbers.

<b>Credit Hours</b>	<b>Date and Time</b>	<b>Title</b>	<b>UAN</b>
1.5	2/26/2026 – 4:00 PM-5:30 PM	Session 2: Designing the Future of Transplantation through Innovative Clinical Research	0530-9999-26-003-L01-P
1.5	2/27/2026 – 8:30 AM-10:00 AM	Session 3: Balancing Ethics with Innovation – The Frontier of Deceased Donor Management Research	0530-9999-26-004-L01-P
1.0	2/27/2026 – 10:30 AM-11:30 AM	CEoT 2026 Keynote Address	0530-9999-26-005-L01-P
1.25	2/27/2026 – 12:00 PM-1:15 PM	CME Lunch Symposium - A New Frontier for Co-stimulatory Blockade	0530-9999-26-015-L01-P
1.25	2/27/2026 – 12:00 PM-1:15 PM	CME Lunch Symposium - Mechanisms and Treatment of Immune Complex GN and C3 GN	0530-9999-26-016-L01-P
1.75	2/27/2026 – 3:45 PM-5:35 PM	Session 5: Smart Match – Transforming Allocation with Innovation and Equity – Kidney Breakout	0530-9999-26-007-L01-P
1.75	2/27/2026 – 3:45 PM-5:35 PM	Session 5: Smart Match – Transforming Allocation with Innovation and Equity – Heart Breakout	0530-9999-26-008-L01-P
1.75	2/27/2026 – 3:45 PM-5:35 PM	Session 5: Smart Match – Transforming Allocation with Innovation and Equity – Liver Breakout	0530-9999-26-009-L01-P
1.75	2/27/2026 – 3:45 PM-5:35 PM	Session 5: Smart Match – Transforming Allocation with Innovation and Equity – Lung Breakout	0530-9999-26-010-L01-P
1.5	2/28/2026 – 8:30 AM-10:00 AM	Session 6: Kidney Breakout - The Changing Landscape of End Organ Disease – Who Gets Transplanted in 2035?	0530-9999-26-011-L01-P
1.5	2/28/2026 – 8:30 AM-10:00 AM	Session 6: Heart Breakout - The Changing Landscape of End Organ Disease – Who Gets Transplanted in 2035?	0530-9999-26-012-L01-P
1.5	2/28/2026 – 8:30 AM-10:00 AM	Session 6: Liver Breakout - The Changing Landscape of End Organ Disease – Who Gets Transplanted in 2035?	0530-9999-26-013-L01-P
1.5	2/28/2026 – 8:30 AM-10:00 AM	Session 6: Lung Breakout - The Changing Landscape of End Organ Disease – Who Gets Transplanted in 2035?	0530-9999-26-014-L01-P



**Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

**Instructions to Receive Credit**

Following the meeting, all participants will receive a link to an online evaluation form. After completing this evaluation, participants may claim a certificate noting the appropriate amount of credit or request a general certificate of attendance.

For pharmacist learners, partial credit may not be awarded, so sessions must be attended in their entirety to claim credit. Participants requesting pharmacy credit must submit requests for credit within 55 days of participation.

**Fee Information & Refund/Cancellation Policy**

Registration fees were collected for this activity. No refunds are permitted after January 26, 2026.

**Disclosures of Relevant Financial Relationships**

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the

Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

<b><i>Name of Faculty or Presenter</i></b>	<b><i>Reported Financial Relationship</i></b>
Ali Zarrinpar, MD	To follow
Allyson Hart, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Alexion Pharmaceuticals
Andrew Barbas, MD	<b>Consulting Fee (e.g., Advisory Board):</b> BMI OrganBank
Andrew Courtright, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Sanofi

THE **POWER OF INNOVATION**

Turning Challenges into Opportunities



February 26-28, 2026 | Scottsdale, Arizona | Westin Kierland Resort and Spa

Angela Lorts, MD, MBA	<b>Consulting Fee (e.g., Advisory Board):</b> Abbott Laboratories <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Abbott Laboratories, ABIOMED, Bayer, Berlin Heart, Syncardia Systems, LLC
Beau Kelly, MD	<b>Stock Shareholder:</b> XVIVO
Bill Fitzsimmons, PharmD	<b>Consulting Fee (e.g., Advisory Board):</b> Eledon Pharmaceuticals, argenx
Carli Lehr, MD, PhD	Nothing to disclose
Carrie Thiessen, MD	Nothing to disclose
Darren Stewart, MS	<b>Consulting Fee (e.g., Advisory Board):</b> Hansa BioPharma
David Goldberg, MD	Nothing to disclose
Deborah Adey, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Vertex Pharmaceuticals <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Hansa Biopharma AB, Natera
David Taber, PharmD	<b>Consulting Fee (e.g., Advisory Board):</b> CareDx
Deborah Levine, MD	Nothing to disclose
Eliseo J. Perez, MD	Nothing to disclose
Erin Lowery, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> CareDx
Errol Bush, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Medtronic
Flavio Vincenti, MD	To follow
Gabe Loor, MD	<b>Consulting Fee (e.g., Advisory Board):</b> ABIOMED, Transmedics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> AtriCure, Inc.
Gabriel Schnickel, MD	Nothing to disclose
Gary Marklin, MD	Nothing to disclose
Jaqueline Henson, MD	Nothing to disclose
Jay Sethuraman, PhD	Nothing to disclose
Jesse Schold, PhD	<b>Consulting Fee (e.g., Advisory Board):</b> eGenesis, Novartis, SANOFI US SERVICES INC., Veloxis Pharmaceuticals, Inc., Verici Dx
John Buccavalas, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Madrigal Pharmaceuticals, MIRUM Pharmaceuticals
John Friedewald, MD	<b>Consulting Fee (e.g., Advisory Board):</b> eGenesis, Eurofins Transplant Genomics, Inc., Mallinckrodt LLC, Memo Therapeutics, Veloxis Pharmaceuticals, Inc., Vertex Pharmaceuticals <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Eurofins Viracor, Inc., Hansa BioPharma, Regeneron Pharmaceuticals, Inc., CSL Behring, Veloxis <b>Speakers' Bureau:</b> SANOFI-AVENTIS U.S. LLC
Jon Snyder, PhD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Alexion Pharmaceuticals, Inc., DEKA Research, Veloxis Pharmaceuticals, Inc.

THE **POWER OF INNOVATION**

Turning Challenges into Opportunities



February 26-28, 2026 | Scottsdale, Arizona | Westin Kierland Resort and Spa

Jondavid Menteer, MD	Nothing to disclose
Joseph Hillenburg	Nothing to disclose
Joseph Leventhal, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Singulera Therapeutics <b>Founder:</b> Tract Therapeutics (company dissolved 12/31/2025)
Kevin Myer, MSHA	Nothing to disclose
Lara Danziger-Isakov, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Astellas Pharma, Eurofins Viracor, Inc., Kamada Ltd., Takeda Pharmaceuticals <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Aicuris, Ansun BioPharma, Merck, Takeda Pharmaceuticals
Lisa McElroy, MD	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Veloxis
Lisa VanWagner, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Madrigal Pharmaceuticals, Novo Nordisk <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Madrigal Pharmaceuticals, W. L. Gore & Associates, Inc.
Mandy Ford, PhD	Consulting Fee (e.g., Advisory Board): Eledon, SANOFI PASTEUR INC., Veloxis Pharmaceuticals, Inc.
Mary Beth Scholand, PhD	<b>Consulting Fee (e.g., Advisory Board):</b> AbbVie, Avalyn, Boehringer Ingelheim, Bristol-Myers Squibb, Insmad, Inc., PureTech Health, Trevi, United Therapeutics
Maryjane Farr, MD	<b>Consulting Fee (e.g., Advisory Board):</b> TransMedics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> FIRE1Foundry
Matthew Cooper, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Natera, Specialist Direct
Matthew Hartwig, MD	<b>Consulting Fee (e.g., Advisory Board):</b> CSL Behring, Intuitive Surgical, Paragonix, Transmedics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Biomed Innovations, Lung Bioengineering
Melissa VonDran, PhD	Nothing to disclose
Neeraj Singh, MD, FAST	<b>Speakers' Bureau:</b> Mallinckrodt LLC
Neha Bansal, MD	Nothing to disclose
Paolo Cravedi, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Apellis Pharmaceuticals, Borealis, Calliditas therapeutics, Cerium Pharmaceuticals, Chinook Therapeutics, eGenesis, Glycoera, Merge Therapeutics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution):</b> Novartis Pharma
Piotr Witkowski, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Sana Therapeutics, Vertex Pharmaceuticals
Roosevelt Bryant, MD	To follow
Shahnawaz Amdani, MD	Nothing to disclose



Shelley Hall, MD	<b>Consulting Fee (e.g., Advisory Board):</b> Abbott Laboratories, CareDX, CVRx, Inc., Natera
Sommer Gentry, PhD	To follow
Sumit Mohan, MD	<b>Consulting Fee (e.g., Advisory Board):</b> DEKA, Sanofi, Specialist Direct, Visterra
Timothy Gong, MD	To follow

The **planners and managers** have the following relevant financial relationships with ineligible companies:

<b>Name of Planner or Manager</b>	<b>Reported Financial Relationship</b>
Rhys Williams, MSN, FNP-C, RN	Nothing to disclose
Conor Hughes	Nothing to disclose
Amanda Glazar	Nothing to disclose
Andrea Funk	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Deborah Sharkey	Nothing to disclose
Shelbi Hogan	Nothing to disclose
JoAnn Gwynn	Nothing to disclose
Jennifer Gillespie	Nothing to disclose
Christine Giannobile	Nothing to disclose
Rachel Patzer, MD	Nothing to disclose

**Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and American Society of Transplantation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.